Scientists test Triple-Threat attack on Tough-to-Treat uterine cancer
NCT ID NCT05603910
Summary
This early-stage study is testing the safety of combining two cancer drugs (lenvatinib and pembrolizumab) with a short, intense course of pelvic radiation. The goal is to see if this three-part approach is safe and tolerable for people with a specific type of recurrent or inoperable endometrial (uterine) cancer that has returned or cannot be surgically removed. Researchers will carefully monitor side effects to find the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.